T. Rowe Price Investment Management, Inc.

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1897612 BALTIMORE, MD

Position in XENE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$130,895,549

+$75,539,366 QoQ

Shares Held

2,168,581

+127.8% QoQ

Ownership

2.24%

of shares outstanding

% of Portfolio

0.09%

of 13F equity value

Holder Rank

#10

of 314 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 94% Shared 0% None 6%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. XENE ranks #17 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$130,895,549	2,168,581	+127.8%	Shares	Sole	2026-08-14
2026-03-31	$55,356,183	951,955	+928.6%	Shares	Sole	2026-05-15
2025-12-31	$4,147,956	92,547	-84.6%	Shares	Sole	2026-02-17
2025-09-30	$24,054,386	599,113	+678.6%	Shares	Sole	2025-11-14
2025-06-30	$2,408,315	76,943	-90.3%	Shares	Sole	2025-08-14
2025-03-31	$26,738,880	796,986	-44.6%	Shares	Sole	2025-05-14
2024-12-31	$56,362,975	1,437,831	-4.4%	Shares	Sole	2025-02-14
2024-09-30	$59,204,920	1,503,808	+4.4%	Shares	Sole	2024-11-14
2024-06-30	$56,141,817	1,439,903	+1.0%	Shares	Sole	2024-08-14
2024-03-31	$61,403,893	1,426,339	+60.1%	Shares	Sole	2024-05-15
2023-12-31	$41,046,322	891,149	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.